California NanoSystems Institute, University of California, Los Angeles, CA 90095, USA; Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095, USA; Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Department of Microbiology, Howard University College of Medicine, Washington, DC 20059, USA.
Virology. 2024 Aug;596:110115. doi: 10.1016/j.virol.2024.110115. Epub 2024 May 17.
Human cytomegalovirus (HCMV) replication relies on a nucleocapsid coat of the 150 kDa, subfamily-specific tegument phosphoprotein (pp150) to regulate cytoplasmic virion maturation. While recent structural studies revealed pp150-capsid interactions, the role of specific amino-acids involved in these interactions have not been established experimentally. In this study, pp150 and the small capsid protein (SCP), one of pp150's binding partners found atop the major capsid protein (MCP), were subjected to mutational and structural analyses. Mutations to clusters of polar or hydrophobic residues along the pp150-SCP interface abolished viral replication, with no replication detected in mutant virus-infected cells. Notably, a single amino acid mutation (pp150 K255E) at the pp150-MCP interface significantly attenuated viral replication, unlike in pp150-deletion mutants where capsids degraded outside host nuclei. These functionally significant mutations targeting pp150-capsid interactions, particularly the pp150 K255E replication-attenuated mutant, can be explored to overcome the historical challenges of developing effective antivirals and vaccines against HCMV infection.
人巨细胞病毒 (HCMV) 的复制依赖于 150 kDa 的核衣壳衣壳蛋白 (pp150),亚科特异性的被膜磷酸蛋白 (pp150) 调节细胞质病毒成熟。尽管最近的结构研究揭示了 pp150-衣壳相互作用,但参与这些相互作用的特定氨基酸的作用尚未通过实验确定。在这项研究中,pp150 和小衣壳蛋白 (SCP),pp150 的结合伴侣之一,位于主要衣壳蛋白 (MCP) 之上,进行了突变和结构分析。沿 pp150-SCP 界面的一簇极性或疏水性残基的突变消除了病毒复制,在突变病毒感染的细胞中未检测到复制。值得注意的是,pp150-MCP 界面上单个氨基酸突变 (pp150 K255E) 显著减弱了病毒复制,与 pp150 缺失突变体不同,在后者中衣壳在宿主核外降解。这些针对 pp150-衣壳相互作用的功能重要突变,特别是 pp150 K255E 复制减弱突变体,可以探索克服开发针对 HCMV 感染的有效抗病毒药物和疫苗的历史挑战。